The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients

Abstract

Cell-free DNA (cfDNA) sequencing provides a non-invasive method for obtaining actionable genomic information to guide personalized cancer treatment, but the presence of multiple alterations in circulation related to treatment and tumor heterogeneity pose analytical challenges. We present the somatic mutation landscape of 70 cancer genes from cfDNA deepsequencing analysis of 21,807 patients with treated, late-stage cancers across >50 cancer types. Patterns and prevalence of cfDNA alterations in major driver genes for non-small cell lung, breast, and colorectal cancer largely recapitulated those from tumor tissue sequencing compendia (TCGA and COSMIC), with the principle differences in alteration prevalence being due to patient treatment. This highly sensitive cfDNA sequencing assay revealed numerous subclonal tumor-derived alterations, expected as a result of clonal evolution, but leading to an apparent departure from mutual exclusivity in treatment-naïve tumors. To facilitate interpretation of this added complexity, we developed methods to identify cfDNA copy-number driver alterations and cfDNA clonality. Upon applying these methods, robust mutual exclusivity was observed among predicted truncal driver cfDNA alterations, in effect distinguishing tumor-initiating alterations from secondary alterations. Treatment-associated resistance, including both novel alterations and parallel evolution, was common in the cfDNA cohort and was enriched in patients with targetable driver alterations. Together these retrospective analyses of a large set of cfDNA deepsequencing data reveal subclonal structures and emerging resistance in advanced solid tumors.

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

“…Understanding mechanistic differences of KRAS alleles and tissue origin are crucial to develop effective treatment strategies for KRAS-dependent cancers. First, KRAS mutations are often a founder genetic event involved in the pathogenesis of PDAC and are consistently found in precancerous pancreatic intraepithelial neoplasms; however, may be acquired as later events during systemic treatment for metastatic disease and have been found as subclonal genetic alterations in a subset of CRC patients ( [25][26][27]). Second, distinct subsets of CRC are characterized by chromosomal instability (CIN) or microsatellite instability (MSI) and are among cancers that exhibit a moderately high tumor mutation burden (TMB) suggesting an extensive degree of genetic heterogeneity [28].…”

Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma

“…The 73gene panel includes the addition of 5 genes to and removal of 2 genes from the list, and the currently used 74-gene panel added one gene. The vast majority of samples in this study were tested using the 73-gene panel [20].…”

Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?

“…Deep-sequencing analysis of 70 cancer genes of 21,807 patients with > 50 treated, advanced cancer types was conducted to explore quantitatively and qualitatively the evolution of actionable resistance alterations having arisen along targeted therapy. ESR1 L536/Y537/D538 was the most common in patients with MBC compared with early stage, treatment naïve tumor tissue, likely reflecting therapy pressure by aromatase inhibitors (AI) [106].…”